Novo Nordisk is expanding access to its GLP-1 drug Wegovy via telehealth, partnering with Hims and Hers, Ro, and LifeMD.

Yes. The majority of Bioma probiotic reviews suggest enhanced digestion, significant bloating reduction, enhanced energy ...

Gen Alpha (children 14 and younger) led the rise of GLP-1 utilization from 2023 to 2024, with an 85% growth rate in that period. But what is behind the sharp increase? 3 factors at play There are ...

A WOMAN has revealed how she has lost 3 stone on weight loss jabs despite still eating takeaways. Liz, from the UK, took to social media to share a typical day of eating while on the injections.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

As broader approval for GLP-1 weight loss drugs spurs higher demand, it’s also causing employer drug spending to spike.

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

According to the Centers for Disease Control and Prevention (CDC), approximately 42% of Americans are obese, and 65% say ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...

Weight is an eternally-pressing topic, but conversations around GLP-1s and other weight loss drugs have brought it to the ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent of her body weight over 18 months. She was feeling physically better, ...